Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T7YE
|
|||
| Drug Name |
LYC-55716
|
|||
| Synonyms |
Cintirorgon; UNII-LPN433P0EA; LPN433P0EA; 2055536-64-4; Cintirorgon [INN]; cintirorgon (proposed INN); SCHEMBL18302870; GTPL10045; LYC55716; BCP28882; EX-A2635; LYC 55716; CS-7496; compound 32J [WO2016201225A1]; HY-104037; 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
Click to Show/Hide
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | ||
| Company |
Lycera Ann Arbor, MI
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H23F6NO6S
|
|||
| Canonical SMILES |
CC(C)(CC1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O
|
|||
| InChI |
1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1
|
|||
| InChIKey |
GULSIMHVQYBADX-FQEVSTJZSA-N
|
|||
| CAS Number |
CAS 2055536-64-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear receptor ROR-gamma (RORG) | Target Info | Agonist | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.